HC Wainwright Issues Positive Outlook for SLN Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Stock analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Silence Therapeutics in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.48). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.74) EPS, FY2028 earnings at ($1.65) EPS, FY2029 earnings at ($1.74) EPS and FY2030 earnings at ($1.77) EPS.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.14). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. The firm had revenue of $0.42 million during the quarter, compared to the consensus estimate of $1.26 million.

Several other research analysts also recently commented on the stock. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Silence Therapeutics Price Performance

Shares of NASDAQ:SLN opened at $7.17 on Tuesday. The firm has a fifty day moving average price of $6.47 and a two-hundred day moving average price of $6.15. Silence Therapeutics has a one year low of $3.69 and a one year high of $8.40. The company has a market cap of $338.67 million, a price-to-earnings ratio of -4.51 and a beta of 1.52.

Institutional Trading of Silence Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SLN. Boothbay Fund Management LLC raised its position in shares of Silence Therapeutics by 1.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after buying an additional 2,409 shares in the last quarter. Massar Capital Management LP purchased a new position in Silence Therapeutics in the 2nd quarter worth $115,000. UBS Group AG raised its position in Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after purchasing an additional 78,854 shares during the period. EHP Funds Inc. purchased a new position in Silence Therapeutics in the 3rd quarter worth $55,000. Finally, Two Sigma Investments LP raised its position in Silence Therapeutics by 6.6% in the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after purchasing an additional 3,935 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.